
Myeloproliferative neoplasms (MPN) are clonal hematological diseases characterized by exacerbated proliferation of cells belonging to the myeloid lineage. Gain of function driver mutations in the Janus Kinase 2 (JAK2), calreticulin (CALR), and thrombopoietin receptor (MPL) genes expressed in the hematopoietic stem cells are the main alterations related to MPN's pathogenesis. These mutations lead to JAK-STAT pathway overactivation, myeloproliferation, inflammation, and bone marrow fibrosis. Along with these genetic alterations, altered immune cell activation may contribute to polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF) pathophysiology. Potential dysregulation in the effector functions of adaptive immune cells may contribute to antitumor response escape and, therefore, favor the clonal expansion of altered myeloid cells in MPN. The present study evaluated the transcriptomic signature of B and T lymphocytes from MPN patients using in silico approaches.
Subjects and methodsPublic peripheral blood microarray data from PV (n = 41), ET (n = 19), MF (n = 9), and control (n = 21) samples were downloaded from the Gene Expression Omnibus (GEO) databank (#GSE26049). Using this data, we performed the Gene Set Enrichment Analysis (GSEA) to identify the immune cell signatures in PV, ET, and MF. We also determined the Differentially Expressed Genes (DEGs) between MPN patients and controls using R software to identify potential alterations in the expression of immune-related genes between MPN patients and controls. In the Human Protein Atlas website (https://www.proteinatlas.org/), we selected the option “single cell type expression cluster (RNA)” and “B-cell – B-cell function”, “T-cells – T-cell receptor” to retrieve the gene signature of B and T lymphocytes. Then, we merged the gene expression of B and T cells with the DEGs retrieved from the three MPN categories to describe the signature of B and T lymphocytes in PV, ET, and MF.
ResultsGSEA revealed that T and B lymphocyte-related genes are enriched in the transcriptome of PV, ET, and MF patients. However, most of the genes associated with T and B cell activation, signaling, and surface membrane receptors were downregulated, mainly in PV and MF samples. In MF samples, GSEA revealed an exclusive positive enrichment in CD4+ T cells, while ET samples showed and unique positive enrichment of naïve and memory B cells, B cell surface receptors, and plasma cells. DEGs analysis also pointed to the downregulation of T cell-related genes compared to controls, corroborating with GSEA data and revealing the potential impairment of biological processes like lymphocyte activation, proliferation, migration, and costimulation. Key B cell-related genes like CD19, CD22, BLK, HLA-DQA1, and immunoglobulin receptors were downregulated in PV and MF DEGs compared to the controls, while the opposite profile was observed in ET samples.
ConclusionB and T lymphocytes from MPN patients present alterations in the expression of key genes related to cell activation, signaling, and effector functions. The gene signature of these cells seem to be different between PV, ET, and MF, suggesting that B cells are more activated in ET and CD4+ T cells in MF. Together, these data suggests that B and T lymphocytes function is altered in MPN.
FundingFAPESP grants #2019/18013-8 and #2022/13366-2.